List of Excipients in Branded Drug ZANOSAR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Parenteral Medicines Inc	ZANOSAR	streptozocin	0703-4636	ANHYDROUS CITRIC ACID
Teva Parenteral Medicines Inc	ZANOSAR	streptozocin	0703-4636	SODIUM HYDROXIDE

Zanosar Excipient Strategy and Commercial Opportunities in Streptozocin

Last updated: August 30, 2026

Zanosar is an injectable streptozocin product for malignant pancreatic islet-cell tumors, including metastatic disease. Its commercial position is defined by orphan oncology demand, a narrow approved use, difficult handling requirements, renal toxicity, and limited formulation complexity. The main excipient opportunity is not a conventional reformulation of an oral product. It is development of a more stable, ready-to-use, lower-waste, easier-to-administer streptozocin presentation that preserves potency and avoids new renal, compatibility, or regulatory risks.

What is Zanosar and how is it formulated?

Zanosar contains streptozocin, an alkylating antineoplastic agent administered by intravenous infusion. The product is supplied as a sterile lyophilized powder in a single-dose vial. FDA labeling directs reconstitution and further dilution before administration.[1]

Product characteristic	Zanosar profile
Active ingredient	Streptozocin
Dosage form	Sterile lyophilized powder for injection
Route	Intravenous infusion
Strength	1 g per vial
Therapeutic area	Malignant pancreatic islet-cell tumors
Regulatory category	FDA-approved orphan oncology product
Key toxicities	Nephrotoxicity, myelosuppression, gastrointestinal toxicity, hepatotoxicity
Reconstitution	Sterile Water for Injection
Further dilution	0.9% Sodium Chloride Injection or 5% Dextrose Injection
Handling	Cytotoxic drug handling procedures apply
Primary commercial issue	Small-volume orphan market with operationally difficult preparation

The formulation is relatively simple compared with liposomal, protein-based, or depot oncology products. The commercial value lies in controlling degradation, preserving sterility, reducing preparation steps, improving pharmacy workflow, and supporting reliable supply.

Zanosar labeling identifies streptozocin as the active component and directs reconstitution with sterile water followed by dilution into an intravenous solution.[1] Public FDA product information does not indicate that Zanosar depends on a complex excipient platform such as a lipid carrier, polymeric nanoparticle, or proprietary sustained-release system.

What excipients are used in Zanosar?

The central excipient strategy for Zanosar is based on a lyophilized powder rather than a liquid formulation.

Current presentation

The marketed product is supplied as a sterile powder requiring pharmacy reconstitution. The labeled diluents are:

• Sterile Water for Injection for initial reconstitution.
• 0.9% Sodium Chloride Injection for subsequent dilution.
• 5% Dextrose Injection for subsequent dilution.[1]

The formulation’s limited excipient burden can reduce risks associated with hypersensitivity, infusion reactions, extractables, and excipient-specific toxicology. The tradeoff is a greater operational burden for oncology pharmacies.

A liquid formulation would need to solve several technical problems:

1. Streptozocin hydrolytic stability in aqueous solution.
2. Long-term potency retention under refrigerated and room-temperature conditions.
3. Compatibility with vial, stopper, syringe, or infusion-bag materials.
4. Protection against microbial contamination after manufacture and during use.
5. Control of degradation products that could affect safety or efficacy.
6. Practical administration at the required clinical concentration.

A liquid presentation that fails any of these tests would have limited commercial value despite eliminating reconstitution.

Candidate excipient classes for a follow-on product

Excipient or platform	Potential purpose	Main development issue
Buffer system	Control pH and slow hydrolysis	Buffer species may accelerate degradation at some pH values
Polyol or sugar	Bulking agent and lyophilization support	May alter cake structure, residual moisture, or reconstitution time
Amino acid	Stabilization during freeze-drying	Requires compatibility and impurity evaluation
Surfactant	Reduce interfacial stress in liquid or reconstituted product	May introduce oxidation, particles, or extractables
Chelating agent	Control metal-catalyzed degradation	Requires justification and safety assessment
Antioxidant	Limit oxidative degradation	May create new impurities or affect assay specificity
Polymer or viscosity modifier	Improve handling or depot behavior	Unlikely to be justified for standard IV use
Preservative	Multi-dose use	Poor fit for a cytotoxic oncology product and likely to increase toxicology burden

For this product, a minimal-excipient approach is commercially more credible than a heavily engineered formulation. The most defensible strategy would likely combine lyophilization with an optimized buffer, bulking agent, or stabilizer, provided the resulting product improves reconstitution or shelf life without creating a new safety profile.

What formulation patents could protect a Zanosar follow-on product?

A follow-on product could seek protection for formulation and manufacturing features rather than the expired active-ingredient composition.

Potential claim categories include:

• A defined streptozocin-to-excipient ratio.
• A specified pH range after reconstitution.
• A lyophilized cake with controlled residual moisture.
• A reconstitution time below a defined threshold.
• A liquid or concentrated solution with a specified impurity profile.
• Stability for a defined period at refrigerated or room temperature.
• Compatibility with selected infusion bags or administration sets.
• Reduced particulate formation after reconstitution.
• A ready-to-administer vial or prefilled container.
• A closed-system transfer configuration for cytotoxic handling.
• A manufacturing process that improves sterility assurance or batch yield.

A formulation patent would need to establish a technically meaningful distinction over earlier streptozocin compositions and standard injectable excipient practice. A claim that merely substitutes one conventional buffer for another would face substantial obviousness risk.

The strongest formulation claims would link composition to measurable performance, such as:

• A defined degradation threshold after storage.
• A specified reconstitution time.
• A controlled impurity limit.
• Stable concentration over the full infusion period.
• Reduced adsorption to administration materials.
• Lower operator exposure during preparation.

What is the Orange Book status of Zanosar?

Zanosar was approved before the modern Hatch-Waxman framework became the principal mechanism for generic injectable competition. The FDA Orange Book should be reviewed for current product listings, patents, and exclusivity codes before relying on a filing or litigation conclusion.[2]

Publicly available product information does not indicate a major active patent estate comparable with newer targeted oncology products. The likely commercial barrier is technical and market-based rather than a broad composition-of-matter patent.

Exclusivity issue	Zanosar assessment
Active ingredient exclusivity	Long expired
Original product patent position	No current composition-of-matter protection expected
Orphan-drug exclusivity	Historical seven-year period has expired
Pediatric exclusivity	No material current barrier identified
Orange Book patent blocking	No prominent active estate identified in public FDA materials
Regulatory pathway for competition	Likely ANDA, subject to product-specific FDA requirements
Main barrier to entry	Small market, sterile manufacturing, hazardous handling, clinical familiarity, and supply economics

The absence of a prominent listed patent does not eliminate regulatory or litigation risk. A competing applicant would still need to evaluate formulation differences, labeling, manufacturing controls, and any later-issued patents that could be relevant to a particular presentation.

When does Zanosar lose exclusivity?

Zanosar’s principal statutory exclusivities have expired. Streptozocin was approved in the early 1980s, and its orphan-drug exclusivity period is no longer active.[1,3]

The relevant commercial conclusion is that Zanosar is not protected today by the original regulatory exclusivity period. A new developer would need to create its own protection through formulation, process, device, packaging, or method-of-use innovation.

Patent-expiration implications

The active ingredient is old, and a new applicant should not assume that legacy Zanosar patents provide a meaningful barrier. The value of a follow-on product would come from:

• Product differentiation.
• Reliable sterile supply.
• Improved pharmacy economics.
• A patentable formulation or container system.
• Better stability or reduced preparation waste.
• Regulatory execution in an orphan oncology indication.

What Paragraph IV challenges could affect Zanosar?

A Paragraph IV challenge would be relevant only if an ANDA applicant certifies that an unexpired listed patent is invalid, unenforceable, or not infringed. If no relevant active Orange Book patent is listed, a Paragraph IV dispute would not be the primary entry mechanism.

Potential challenge areas would include:

• A listed formulation patent.
• A reissued or later-issued patent covering a specific injectable composition.
• A method-of-use patent tied to a dosing schedule or tumor type.
• A patent covering a concentrated or ready-to-use presentation.

For a generic streptozocin product, the more probable route would be a standard ANDA based on pharmaceutical equivalence and bioequivalence principles applicable to an injectable product. The applicant would still need to address:

• Same active ingredient.
• Same route of administration.
• Equivalent dosage form and strength.
• Sterility and particulate controls.
• Container-closure integrity.
• Reconstitution and dilution instructions.
• Labeling differences.
• Stability and in-use data.

A 505(b)(2) application could be more suitable for a materially different product, such as a ready-to-use solution, a new concentration, a new container, or a modified administration method. That pathway could support three-year exclusivity for certain new clinical investigations, but it would not recreate the original active-ingredient exclusivity.

What formulation opportunities exist for a Zanosar competitor?

Ready-to-use liquid vial

A ready-to-use liquid vial would eliminate initial reconstitution. Its commercial value would depend on sufficient shelf life, low degradation, and acceptable cold-chain requirements.

Advantages include:

• Fewer pharmacy preparation steps.
• Lower risk of reconstitution errors.
• Reduced operator handling.
• Easier dose preparation.
• Potentially lower product waste.

Risks include:

• Hydrolytic degradation.
• Higher stability costs.
• Greater sensitivity to temperature excursions.
• More demanding container-closure requirements.
• Potentially shorter dating than a lyophilized product.

Concentrated solution

A concentrated solution could allow direct transfer into a compatible infusion container after controlled dilution. This format would reduce vial count and preparation time, but concentration-dependent precipitation, adsorption, and local tolerability would need evaluation.

Improved lyophilized formulation

The most practical opportunity may be an improved powder rather than a liquid. A redesigned lyophilized product could target:

• Faster reconstitution.
• Lower residual moisture.
• Improved cake appearance and handling.
• Longer shelf life.
• Reduced foaming.
• Lower extractable and particulate burden.
• Better recovery from the vial.
• Reduced overfill and product waste.

This approach would preserve the stability advantages of a dry product while improving pharmacy workflow.

Closed-system administration kit

A kit combining the drug vial, transfer device, compatible diluent, and administration components could address cytotoxic handling. The kit could support a device or combination-product strategy, although the regulatory pathway would become more complex.

A closed-system transfer device would be commercially valuable if it reduced preparation time and exposure risk without imposing high per-dose costs. Device patents could provide a stronger competitive position than a narrow excipient patent, especially if the system is compatible with oncology pharmacy protocols.

Prefilled syringe or cartridge

A prefilled syringe is less likely to be attractive for a cytotoxic agent requiring individualized dosing and infusion dilution. It may be relevant for a defined dose presentation, but the container, stability, dose flexibility, and hazardous-drug handling issues create substantial development constraints.

How strong is the patent estate for Zanosar?

The patent estate is likely weak at the active-ingredient level and potentially moderate for a genuinely differentiated formulation or delivery system.

Patent layer	Relative strength	Commercial assessment
Streptozocin composition of matter	Low	Historical protection is expired
Basic injectable formulation	Low	Conventional claims face obviousness risk
Optimized lyophilized formulation	Moderate	Stronger if linked to stability or reconstitution data
Ready-to-use liquid	Moderate to high	Depends on unexpected stability and impurity control
Container-closure system	Moderate	Can protect a practical manufacturing and handling advantage
Cytotoxic transfer device	Moderate to high	Potentially valuable if adoption and compatibility are strong
New dosing method	Variable	Requires clinical support and Orange Book strategy
Manufacturing process	Moderate	May be difficult to detect in an accused product

Process patents can be commercially useful but are harder to enforce because infringement may occur inside a competitor’s manufacturing facility. Formulation and device claims are more visible in the marketed product and usually offer better enforcement leverage.

What method-of-use patents could protect streptozocin?

Method-of-use protection could target a distinct clinical use, dosing schedule, patient population, or combination regimen. Potential areas include:

• Specific pancreatic neuroendocrine tumor subtypes.
• A defined dosing schedule.
• Use after failure of another systemic therapy.
• Combination treatment with a targeted agent.
• Biomarker-selected patients.
• Renal-protection protocols.
• Use in a specific line of therapy.

The commercial value of a method-of-use patent depends on whether the protected use can be incorporated into labeling and whether prescribers would use the product for the patented indication. A broad method claim may be difficult to enforce where the same drug is used across multiple tumor settings.

The main clinical limitation is toxicity. Any new method-of-use program would need to show that the dosing or combination strategy preserves antitumor activity while managing renal and marrow toxicity.

What FDA regulatory status affects commercial entry?

FDA approval of Zanosar establishes an important regulatory reference point, but it does not guarantee that every alternative formulation can use the ANDA pathway.

ANDA strategy

An ANDA is most attractive for a product that matches the reference product in dosage form, strength, route, and essential labeling. A sterile injectable applicant would face a demanding chemistry, manufacturing, and controls review.

The main ANDA issues are likely to include:

• Sterile manufacturing validation.
• Endotoxin and particulate control.
• Drug-product assay and impurity characterization.
• Reconstitution performance.
• Stability after dilution.
• Container-closure integrity.
• Extractables and leachables.
• Cytotoxic handling instructions.

505(b)(2) strategy

A 505(b)(2) application may be appropriate for:

• A ready-to-use liquid.
• A different concentration.
• A new diluent system.
• A new container or administration device.
• A revised dosing or administration method.
• A product supported by new clinical studies.

This pathway can support differentiation but may require clinical bridging, human factors work, or additional safety data. It may also trigger a more complex exclusivity and patent analysis.

Orphan-drug considerations

The pancreatic islet-cell tumor market is narrow. A new product could potentially qualify for orphan designation if it meets FDA criteria, but orphan status would not automatically create protection against the original product for an already established indication. Any new orphan exclusivity would depend on the specific indication, clinical superiority, and regulatory eligibility.

What generic entry risks exist for Zanosar?

Generic entry risk is structurally high because the active ingredient is old and the product’s original exclusivity has expired. Actual entry risk is moderated by market economics.

Risk factor	Effect on entry
Old active ingredient	Increases entry feasibility
Limited patent estate	Reduces legal barrier
Sterile injectable manufacturing	Raises capital and compliance costs
Cytotoxic handling	Raises occupational and facility requirements
Small patient population	Limits expected revenue
Orphan oncology pricing	Can improve revenue per treatment
Low competitor count	May support attractive pricing
Supply interruptions	Create opportunity for a reliable entrant
Physician familiarity	Favors the established product
Renal toxicity	Raises clinical and pharmacovigilance burden

A generic applicant may face a classic orphan-injectable problem: the product can carry a high price, but annual demand may be too low to support multiple manufacturers. The market may support one or two disciplined entrants rather than a crowded generic field.

Which companies could challenge or compete with Zanosar?

The competitive field is likely to consist of three groups:

1. Generic sterile-injectable manufacturers with oncology capabilities.
2. Specialty pharmaceutical companies serving rare cancers.
3. Contract development and manufacturing organizations partnering with an established oncology marketer.

A successful competitor would need more than an ANDA. It would need:

• Reliable sterile capacity.
• Controlled-substance and hazardous-drug procedures.
• Specialty distribution.
• Access to neuroendocrine tumor centers.
• Reimbursement and coding support.
• A supply plan for a low-volume product.
• Pharmacovigilance capability for renal and hematologic toxicity.

The strongest commercial positioning would be "same active ingredient, easier preparation, dependable supply," rather than an unsupported clinical-superiority claim.

What licensing deals could support a Zanosar follow-on product?

A licensing strategy could combine four assets:

Asset	Potential partner
Streptozocin formulation technology	Drug-delivery or injectable-formulation company
Sterile manufacturing	CDMO with cytotoxic capability
Closed-system transfer technology	Medical-device company
Commercial distribution	Specialty oncology marketer

A specialty pharmaceutical company could license an improved formulation from a formulation developer while outsourcing manufacture to a cytotoxic CDMO. The deal structure would likely favor milestone payments tied to formulation selection, FDA acceptance, approval, and commercial launch.

The most valuable license would cover a product that has already demonstrated:

• At least 24 months of meaningful stability.
• Acceptable reconstitution or transfer performance.
• Compatible packaging.
• A scalable sterile process.
• No material increase in renal or infusion toxicity.
• A credible ANDA or 505(b)(2) pathway.

How does Zanosar compare with other injectable orphan oncology products?

Criterion	Zanosar	Newer targeted injectable oncology product
Active ingredient age	Older	Often recent
Patent protection	Limited	Frequently extensive
Formulation complexity	Low to moderate	Moderate to high
Clinical market	Narrow	May be narrow or broad
Generic pathway	Potentially accessible	Often delayed by patents
Differentiation opportunity	Formulation, handling, supply	Clinical profile, biomarker, delivery
Main commercial risk	Small market and manufacturing economics	Patent expiry and clinical competition
Excipient opportunity	Stability and workflow	Delivery, exposure, immunogenicity, or targeting

Zanosar is more suitable for a low-cost, focused lifecycle-management strategy than for a large platform investment. The opportunity is strongest where the developer can combine formulation improvement with manufacturing reliability and specialty distribution.

What is the revenue exposure and market opportunity?

Zanosar revenue is not reported as a major standalone product line in public filings. The addressable market is constrained by the rarity of malignant pancreatic islet-cell tumors and the use of alternative systemic treatments, surgery, locoregional therapy, and targeted agents.

Commercial upside could come from:

• Shortages or supply interruptions.
• Improved penetration into specialty cancer centers.
• Lower waste from better vial utilization.
• Premium pricing for ready-to-use presentation.
• Contract supply arrangements with hospitals.
• International registration in jurisdictions with limited access.
• Combination use in clinical development.

The market does not support a broad, high-volume excipient program. A viable product should be designed around a narrow customer base, high pharmacy value, and low manufacturing waste.

What geographic coverage and manufacturing barriers matter?

The United States is the most important regulatory reference market because of FDA approval, orphan oncology reimbursement, and the Orange Book framework. European and other markets require separate regulatory and patent reviews.

Geographic opportunity depends on:

• Local registration of streptozocin.
• Availability of neuroendocrine tumor treatment centers.
• Reimbursement for orphan oncology drugs.
• Import requirements for sterile cytotoxic products.
• Local pharmacovigilance obligations.
• Patent status for any new formulation or device.

Manufacturing is a meaningful barrier. Streptozocin production and filling require validated handling of a cytotoxic compound, dedicated or appropriately controlled facilities, containment procedures, and specialized worker-protection systems. A developer without internal cytotoxic capability would likely rely on a qualified CDMO.

Key Takeaways

• Zanosar is a sterile lyophilized streptozocin injection for malignant pancreatic islet-cell tumors.
• Its current formulation relies on reconstitution with Sterile Water for Injection and further dilution with saline or dextrose.
• The active ingredient and original regulatory exclusivities are expired.
• The principal commercial barrier is not a strong active-ingredient patent estate. It is the small orphan market, sterile manufacturing burden, cytotoxic handling, and limited pharmacy demand.
• The strongest excipient opportunity is an improved lyophilized formulation with faster reconstitution, better stability, lower residual moisture, or reduced waste.
• A ready-to-use liquid could command greater commercial value but faces substantial aqueous stability and impurity risks.
• Device and container-closure patents may provide stronger protection than conventional excipient claims.
• An ANDA is likely for a substantially equivalent injectable product. A 505(b)(2) application may be more suitable for a materially different liquid, concentration, device, or administration method.
• Commercial success depends on supply reliability, specialty distribution, and pharmacy workflow improvements rather than broad volume growth.

FAQs

Can a new excipient formulation of Zanosar receive FDA approval without new efficacy trials?

Potentially. A substantially equivalent injectable may fit an ANDA pathway, while a materially different formulation may require a 505(b)(2) application and supporting bridging or clinical data.

Is a ready-to-use streptozocin product commercially attractive?

Yes, if it delivers materially longer stability, lower preparation burden, and acceptable impurity control. The small market limits the price and development budget that customers will support.

Could a Zanosar competitor obtain new orphan exclusivity?

Possibly, but only for an eligible orphan indication meeting FDA requirements. Orphan status would not automatically provide exclusivity for the same established indication without satisfying applicable clinical and regulatory standards.

Are formulation patents likely to block generic streptozocin entry?

A narrow, well-supported formulation patent could delay a specific presentation. Conventional excipient substitutions without demonstrated technical effect would face greater validity risk.

What is the most practical product-development strategy for Zanosar?

An optimized lyophilized vial, supported by a cytotoxic-handling kit and dependable sterile supply, is likely more practical than a complex delivery platform or prefilled system.

References

1. U.S. Food and Drug Administration. (2022). Zanosar (streptozocin) for injection: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Orphan drug designations and approvals database.